Get in touch
555-555-5555
mymail@mailservice.com
TolerogenixX
Founding year: 2015
Management:
Dr. Anita Schmitt, Dr. Matthias Schaier, Prof. Dr. Christian Morath
Head office: Heidelberg
Industry: Medicine / pharma
Investment phase:
Start-up phase
TolerogenixX, a spin-off from the University of Heidelberg, offers a new approach to immunosuppression involving MIC cell therapy.
This is a curative ATMP approach to treatment that promotes sustainable regulation of the immune system in people who have received transplants or patients with autoimmune diseases.